🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
46.53
+0.12 (0.26%)
Nov 20, 2026, 4:00 PM EST - Market closed

Enliven Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
36.4133.823.7817.667.774.29
Research & Development
98.9585.8680.7864.5731.0220.47
Operating Expenses
135.36119.66104.5582.2338.7924.76
Operating Income
-135.36-119.66-104.55-82.23-38.79-24.76
Interest & Investment Income
21.916.0114.8911.971.130.02
Other Non Operating Income (Expenses)
-0.02-0.05-0-0.02--
EBT Excluding Unusual Items
-113.48-103.69-89.67-70.28-37.66-24.74
Merger & Restructuring Charges
----1.3--
Other Unusual Items
--0.87---
Pretax Income
-113.48-103.69-88.79-71.58-37.66-24.74
Income Tax Expense
--0.23---
Net Income
-113.48-103.69-89.02-71.58-37.66-24.74
Net Income to Common
-113.48-103.69-89.02-71.58-37.66-24.74
Net Income Growth
------
Shares Outstanding (Basic)
6757473638
Shares Outstanding (Diluted)
6757473638
Shares Change
25.73%20.38%32.43%1037.74%-60.02%56.70%
EPS (Basic)
-1.68-1.83-1.89-2.01-12.05-3.17
EPS (Diluted)
-1.68-1.83-1.89-2.01-12.05-3.17
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-66.41-70.46-73.24-61.42-32.69-19.33
Free Cash Flow Per Share
-0.99-1.24-1.56-1.73-10.46-2.47
EBITDA
-135.28-119.4-104.24-81.93-38.58-24.65
D&A For EBITDA
0.080.260.320.30.220.12
EBIT
-135.36-119.66-104.55-82.23-38.79-24.76
SEC Filings: 10-K · 10-Q